IRAK4 and rheumatoid arthritis: It showed that IRAK4 could antagonize inflammatory osteolysis, and IRAK4 inhibitor (IRAK4i) therapy attenuated rheumatoid arthritis (RA) disease activity by blocking M1 macrophage activation and also disrupted osteoclastogenesis [22].